Multiple myeloma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KPD Variant #03 | — | R 168 358 | 28d | — | — | — | — | — |
Pomalidomide and Prednisone Variant #02 | — | R 19 187 | 28d | — | — | — | — | — |
RVD Variant #01 | — | R 10 486 | 28d | ~43.0 mo | — | ~47 | ~R 492 828 PFS proxy · indirect | 9 |
Bortezomib and Cyclophosphamide Variant #01 | — | R 1 165 | 14d | — | — | — | — | — |
Pomalidomide monotherapy N/A - secondary systemic drug | — | R 0 | 28d | ~2.7 mo | — | ~3 | ~R 0 PFS proxy · indirect | 1 |
5 of 5 regimens shown